Managing Gynecologic Screening

Applies ASCCP risk-based cervical cancer screening guidelines, Bethesda System cytology classification, HPV co-testing protocols, and colposcopy indications for evidence-based cervical cancer prevention.

Why This Skill Exists

Cervical cancer is a largely preventable disease through screening and HPV vaccination. The 2019 ASCCP Risk-Based Management Consensus Guidelines replaced the prior algorithm-based approach with a risk-estimation framework where management is determined by the patient's estimated risk of CIN 3+ rather than by individual test results alone. The Bethesda System for Reporting Cervical Cytology provides the standardized terminology (ASC-US, LSIL, HSIL, AGC, etc.) that clinicians must use when documenting results.

Errors in screening management — over-screening low-risk patients, under-screening high-risk patients, or failing to refer for colposcopy when indicated — contribute to both unnecessary procedures and missed cancers. This skill ensures that every screening decision follows the ASCCP risk thresholds and is properly documented.

Checkpoint A: Pre-Draft Intake (Mandatory)

Patient age — screening recommendations vary by age group. (Default: from demographics)
HPV vaccination status — vaccinated patients still require screening per guidelines. (Default: from immunization record)
Screening history — last Pap/HPV test date and results? Any prior abnormal results? (Default: from prior lab reports)
HIV status — HIV-positive patients have separate screening intervals. (Default: from chart)
Immunosuppression status — organ transplant, chronic steroid use, other immunosuppression? (Default: from problem list)
Prior treatment history — LEEP, cone biopsy, cryotherapy, or hysterectomy? (Default: from surgical history)
Pregnancy status — Pap screening may be performed but colposcopy management differs in pregnancy. (Default: confirm)
DES exposure — in utero DES exposure requires specialized screening. (Default: ask if age-appropriate)

Documents to Request

Prior Pap smear results with Bethesda classification
HPV testing results (genotyping: HPV 16/18 vs. other high-risk types)
Colposcopy reports and biopsy pathology
Prior LEEP/cone operative and pathology reports
HIV test results
Immunization records (HPV vaccine series)

Step 1: Apply Age-Based Screening Intervals

Per USPSTF/ACOG/ACS/ASCCP recommendations:

| Age Group | Screening Recommendation | |---|---| | < 21 years | No screening regardless of sexual history or HPV vaccination | | 21–24 years | Cytology alone every 3 years; NO HPV co-testing | | 25–29 years | Cytology every 3 years, OR HPV primary screening every 5 years (per ACS 2020 update) | | 30–65 years | Cytology + HPV co-testing every 5 years (preferred), OR cytology alone every 3 years, OR HPV primary screening every 5 years | | > 65 years | Discontinue if adequate prior screening (3 consecutive negative cytology or 2 consecutive negative co-tests in prior 10 years, most recent within 5 years) and no history of CIN 2+ in prior 25 years | | Post-hysterectomy (with cervix removed) | Discontinue if no history of CIN 2+ and cervix fully removed |

Special populations:

HIV-positive: Begin screening at age 21, cytology annually; co-testing every 3 years if age ≥ 30 with normal results × 3
Immunosuppressed (non-HIV): Screen per HIV guidelines
In utero DES exposure: Annual cytology starting at age of diagnosis

Step 2: Interpret Results Using the Bethesda System

Cytology Categories (Bethesda 2014)

| Bethesda Category | Meaning | Clinical Significance | |---|---|---| | NILM | Negative for intraepithelial lesion or malignancy | Normal result | | ASC-US | Atypical squamous cells of undetermined significance | Mildly abnormal; reflex HPV testing indicated | | ASC-H | Atypical squamous cells, cannot exclude HSIL | Higher concern; colposcopy recommended | | LSIL | Low-grade squamous intraepithelial lesion | Corresponds to HPV effect / CIN 1 | | HSIL | High-grade squamous intraepithelial lesion | Corresponds to CIN 2/3; colposcopy required | | AGC | Atypical glandular cells | Requires colposcopy + endocervical curettage ± endometrial biopsy | | AIS | Adenocarcinoma in situ | Requires colposcopy, ECC, and excisional procedure | | SCC | Squamous cell carcinoma | Invasive cancer — urgent gynecologic oncology referral |

HPV Results

HPV negative — low risk, return to routine screening
HPV positive (other high-risk, non-16/18) — risk depends on cytology
HPV 16 positive — highest risk; colposcopy regardless of cytology
HPV 18 positive — high risk; colposcopy regardless of cytology

Step 3: Apply the 2019 ASCCP Risk-Based Framework

Management is based on the estimated CIN 3+ risk using current and prior test results:

| Estimated CIN 3+ Risk | Recommended Action | |---|---| | < 0.15% | Return to routine 5-year screening | | 0.15–0.54% | Return in 3 years for repeat testing | | 0.55–3.9% | Return in 1 year for repeat testing | | 4.0–24% | Colposcopy recommended | | 25–59% | Colposcopy with biopsy; treatment acceptable | | 60–100% | Excisional treatment recommended (LEEP or cold knife cone) |

Key clinical action thresholds:

ASC-US / HPV negative: Return in 3 years (low risk)
ASC-US / HPV positive (non-16/18): Return in 1 year
ASC-US / HPV 16 or 18 positive: Colposcopy
LSIL / HPV negative (ages 25+): Return in 1 year
LSIL / HPV positive: Colposcopy
HSIL (any HPV result): Colposcopy; expedited treatment (LEEP) acceptable if not pregnant
AGC: Colposcopy + ECC + endometrial biopsy (if age ≥ 35 or risk factors for endometrial cancer)

Step 4: Colposcopy Documentation Requirements

When colposcopy is performed, document:

Indication — cytology result, HPV status, ASCCP risk estimate
Adequacy — visualization of entire squamocolumnar junction (SCJ) — adequate vs. inadequate
Findings — acetowhite epithelium, punctation, mosaicism, atypical vessels, lesion size and location (clock positions)
Biopsy location(s) — number and clock positions of biopsies taken
Endocervical curettage (ECC) — performed or not, indication
Impression — low-grade vs. high-grade colposcopic impression
Pathology results — CIN 1, CIN 2, CIN 3, AIS, invasive carcinoma
Management plan — surveillance vs. excision based on pathology and ASCCP guidelines

Checkpoint B: Post-Draft Alignment (Mandatory)

Is the screening interval appropriate for the patient's age and risk profile?
Are all test results documented with Bethesda terminology for cytology and specific HPV genotype data?
Does the management plan match the ASCCP risk-based recommendation for the test result combination?
Is the colposcopy referral documented when indicated, or is the surveillance plan clearly stated?
Are special populations flagged — HIV, immunosuppressed, post-treatment, DES exposure?

Quality Audit

[ ] Patient age documented and screening interval matches age-based recommendation
[ ] Cytology result documented using Bethesda System terminology
[ ] HPV result documented with genotype specificity (16, 18, other high-risk, negative)
[ ] ASCCP risk estimate or risk category is stated
[ ] Colposcopy referral documented when CIN 3+ risk ≥ 4%
[ ] Colposcopy adequacy (SCJ visualization) documented when performed
[ ] Biopsy results documented with CIN grade
[ ] ECC performed and results documented for AGC or unsatisfactory colposcopy
[ ] Prior abnormal results are referenced when estimating current risk
[ ] Treatment plan (surveillance vs. excision) is stated with next follow-up date
[ ] HIV and immunosuppression screening protocols applied when applicable
[ ] Post-treatment surveillance documented (at 6 months, 12 months, then annually × 3 years, then every 3 years × 25 years)
[ ] HPV vaccination status documented and vaccine offered if eligible (up to age 45)

Guidelines

Use Bethesda terminology exclusively — never write "Class II" or "mild dysplasia" in place of the standardized Bethesda terms.
Always pair cytology with HPV result — isolated cytology interpretation without HPV context leads to incorrect risk estimation.
Do not over-screen — annual Pap smears are not recommended for average-risk patients over age 30 with negative co-testing; the interval is 5 years.
Age 21–24 is a special group — LSIL and ASC-US in this age group are managed conservatively due to high regression rates. Do NOT perform HPV co-testing.
AGC triggers a broader workup — always include ECC and consider endometrial biopsy, especially in patients ≥ 35 or with abnormal bleeding.
Post-treatment surveillance is 25 years — patients with treated CIN 2+ remain at elevated risk for at least 25 years and must not return to standard population-based screening intervals.
Document the "adequate negative prior" determination when discontinuing screening at age 65 — list the specific tests and dates that meet exit criteria.